UroToday2d
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
Bladder cancer is a highly recurrent disease with few treatment options available to patients,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “This program reflects our ...
UroToday4d
Transition in Quality Of Life Among Older Patients With Bladder Cancer and Its Association With Treatment: A Clustering Approach
Purpose: To classify older patients with bladder cancer (BC) based on quality-of-life (QoL) measures and explore the clusters transitions over a 2-year period and patient characteristics, BC stages, ...
UroToday3d
Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval.
The optimal regimen for 177Lu-labeled prostate-specific membrane antigen-targeted radioligand therapy, including treatment intervals, remains under study, with evidence suggesting shorter intervals ...
UroToday4d
Survival of Men with Metastatic Hormone-Sensitive Prostate Cancer and Adrenal-Permissive HSD3B1 Inheritance - Beyond the Abstract
There is now a plethora of mechanistic and clinical evidence that the adrenal-permissive HSD3B1 allele allows for prostate cancer to increase the synthesis of potent non-gonadal androgens. Further, ...
UroToday3d
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies.
This summary includes information from the ARCHES and ENZAMET follow-up studies. Both studies looked at enzalutamide treatment for people with metastatic hormone-sensitive prostate cancer (known as ...
UroToday3d
Dense Collagen I as a Biomimetic Material to Track Matrix Remodelling in Renal Carcinomas.
Aims: Renal tissue is a dynamic biophysical microenvironment, regulating healthy function and influencing tumor development. Matrix remodelling is an iterative process and aberrant tissue repair is ...
UroToday4d
Positive Guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III Trial in Patients with Recurrence of Prostate Cancer
United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for 64Cu-SAR-bisPSMA diagnostic in prostate cancer patients with biochemical recurrence ...
UroToday4d
Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy
Purpose/objectives: Rectal spacers have been shown to reduce rectal side effects in patients receiving prostate radiation. However, concerns remain regarding precise and reproducible gel injection. We ...
UroToday5d
Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naïve Prostate Cancer.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA ...
UroToday5d
New "conservative" treatments for Peyronie's disease-real alternatives or expensive pastime?.
Conservative treatment of Peyronie's disease (induratio penis plastica, IPP) remains largely unsuccessful despite decades of research, as the exact disease pathogenesis remains unclear. Currently, IPP ...
UroToday4d
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1) - Beyond the Abstract
Background: The therapeutic advancements based on immune-oncology (IO) combinations have revolutionized renal cell carcinoma (RCC) management. However, patients who have progressive disease as best ...